Skip to main content
ISTH 2023 Main banner
Back

    Poster Networking

    Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies

    Poster Networking Session

    PB0334 - Immune-Mediated Thrombotic Thrombocytopenic Purpura Landscaping in Gulf Countries: A Real-World Evidence Study (ATHENA Study)

    Sunday, June 25, 2023
    18:30 – 19:30 ET
    Room: Exhibition

      Presenting Author(s)

    • Muna Al Rasheed, FRCPC ABIM

      Consultant Hematologist
      Al Adan Hospital, Kuwait
      Kuwait City, Al Ahmadi, Kuwait

      • Co-Author(s)

    • FA

      Faisal Alsayegh

      Associate Professor
      College of Medicine, Kuwait University, Kuwait
      Kuwait City, Al Asimah, Kuwait

    • HA

      Hasan AaL Yaseen

      Professor; Adult Clinical Hematologist
      Dubai Hospital, Dubai, United Arab Emirates
      Dubai, Dubai, United Arab Emirates

    • MM

      Mahmoud Marashi

      Professor; Consultant Hematologist
      Dubai Hospital, Dubai, United Arab Emirates
      Dubai, Dubai, United Arab Emirates

    • HO

      Hani Osman

      Consultant Hematologist
      Tawam Hospital, Al Ain, United Arab Emirates
      Al Ain, Abu Dhabi, United Arab Emirates

    • MA

      Murtadha Al-Khabori

      Senior Consultant Hematologist
      Sultan Qaboos University Hospital, Muscat, Oman
      Al Seeb, Masqat, Oman

    • SA

      Sabria Al-Hashami

      Senior Consultant Hematologist
      Royal Hospital, Muscat, Oman
      Muscat, Masqat, Oman

    • RT

      Ruba Taha

      Consultant Clinical Hematologist
      Hamad Medical Corporation, Doha, Qatar
      Doha, Ad Dawhah, Qatar

    • HA

      Hussein Al Saeed

      Consultant Hematologist
      Qatif Central Hospital, Qatif, Saudi Arabia
      Al Qatif, Ash Sharqiyah, Saudi Arabia

    • MS

      Maha Sallam

      Consultant Hematologist
      King Fahad Hospital Hofuf, Saudi Arabia
      Al Hofuf, Ash Sharqiyah, Saudi Arabia

    • FA

      Farjah AlGahtani

      Consultant Hematologist
      King Saud University, Riyadh, Saudi Arabia
      Riyadh, Ar Riyad, Saudi Arabia

    • FA

      Fahad Almohareb

      Consultant of Adult Hematology
      King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
      Riyadh, Ar Riyad, Saudi Arabia

    • MQ

      Mohamad Qari

      Consultant Hematologist
      King Abdulaziz University Hospital, Jeddah, Saudi Arabia
      Jeddah, Makkah, Saudi Arabia

    • HS

      Hind Salama

      Consultant Hematologist
      King Abdulaziz Medical City, Riyadh, Saudi Arabia
      Riyadh, Ar Riyad, Saudi Arabia

    • HM

      Hafiz Malhan

      Consultant Hematologist
      Prince Mohammed bin Nasser Hospital, Jizan, Saudi Arabia
      Jazan, Jizan, Saudi Arabia

    • AA

      Adel Aljatham

      Consultant Hematologist
      King Saud Medical City, Riyadh, Saudi Arabia
      Riyadh, Ar Riyad, Saudi Arabia

    • ZC

      Zahir Chouikrat

      Real World & Medical Evidence Generation Lead
      Sanofi
      Dubai, Dubai, United Arab Emirates

    • MR

      Magdy Rabea

      Medical Manager, Hematology & Oncology, KSA and Gulf Countries
      Sanofi
      Jeddah, Makkah, Saudi Arabia

    • AM

      Ahmed Mekky

      Medical Advisor, Oncology & Rare Blood Disorders
      Sanofi
      Dubai, Dubai, United Arab Emirates

    • MN

      Mina Nagib

      Senior Scientific Advisor
      Bristol Myers Squibb; Formerly Sanofi
      Dubai, Dubai, United Arab Emirates

    Background: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder, caused by autoantibody-mediated deficiency of ADAMTS13, and is associated with significant morbidity and mortality. Real-world data on iTTP epidemiology in Arabian Gulf countries are lacking.

    Aims: This study assessed iTTP burden and management patterns in the Arabian Gulf region.

    Methods: This real-world, multinational, multicenter, observational, retrospective, non-interventional study used patient records and electronic medical healthcare records data between June 2018 and November 2021 from patients (≥12 years of age) with iTTP (initial or recurrent) diagnosed within 36 months before index date (cut-off: November 30, 2021).

    Results: Data were extracted from 60 patient records. Patient characteristics are described in Table 1. All patients were medically managed. The most common treatment regimen was rituximab + corticosteroids + therapeutic plasma exchange (TPE; 61.7%); 11.7% of patients received caplacizumab. The proportion of patients achieving remission by treatment type are shown in Table 2. In total, 95% of patients received TPE, with a median of 8 (1–41) sessions/patient. Platelet normalization was achieved after a median of 6 (3–32) days in the overall population and 4 (2–10) days in patients treated with caplacizumab. Of those receiving caplacizumab, median time before caplacizumab initiation after last event was 6 (0–16) days. ADAMTS13 testing was performed in 56.7% of patients, with results available after a median period of 11 (1–96) days. Laboratory markers for lactate dehydrogenase and creatinine significantly improved after treatment (P < 0.05). Six patients (10%) died during the study period; 4 deaths were related to iTTP. No patients treated with caplacizumab died.

    Conclusion(s): TPE, corticosteroids, and rituximab were the most frequently used iTTP treatments. Overall iTTP-related mortality was 10%; however, no patients treated with caplacizumab died. These data highlight the disease burden in the Arabian Gulf region and can guide healthcare resource reallocation.

    Funded by Sanofi.